Publications by authors named "Samanta Cupini"

Claim this Profile
F
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
Carlotta Antoniotti, Federica Marmorino, Daniele Rossini, Hans Joachim Schmoll, Sara Lonardi, Samanta Cupini

Eur J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib.
Federico Villanacci, Diego Prost, Francesco Pieri, Julien Boetto, Vanna Zucchi, Samanta Cupini

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rebound Growth Following Temporary Discontinuation of BRAFi and MEKi in a Patient With Multifocal BRAFV600E-Mutant Primary Brain Tumor.
Antonio Pisano, Samanta Cupini, Orazio Santo Santonocito, Bianca Pollo, Rosina Paterra

Neurology· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rebound Growth Following Temporary Discontinuation of BRAFi and MEKi in a Patient With Multifocal BRAFV600E-Mutant Primary Brain Tumor.
Antonio Pisano, Samanta Cupini, Orazio Santo Santonocito, Bianca Pollo, Rosina Paterra

Neurology· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy-induced eczema treated with dupilumab.
Angelo Massimiliano D'Erme, Cristian Fidanzi, Nicolò Mori, Gianna Musettini, Samanta Cupini

J Eur Acad Dermatol Venereol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.
Luigi Coltelli, Chiara Finale, Gianna Musettini, Andrea Fontana, Maria Teresa Barletta, Samanta Cupini

Clin Exp Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
Valentina Fanotto, Daniele Rossini, Mariaelena Casagrande, Francesca Bergamo, Andrea Spagnoletti, Samanta Cupini

Cancers (Basel)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Alessandra Boccaccino, Daniele Rossini, Alessandra Raimondi, Martina Carullo, Sara Lonardi, Samanta Cupini

Eur J Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status.
Francesca Lessi, Mariangela Morelli, Sara Franceschi, Paolo Aretini, Michele Menicagli, Samanta Cupini

Int J Mol Sci· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO.
Emanuela Dell'Aquila, Daniele Rossini, Alessandro Galletti, Marco Stellato, Alessandra Boccaccino, Samanta Cupini

Clin Colorectal Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.
Luigi Coltelli, Giacomo Allegrini, Paola Orlandi, Chiara Finale, Andrea Fontana, Samanta Cupini

NPJ Breast Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
Roberto Moretto, Daniele Rossini, Iolanda Capone, Alessandra Boccaccino, Federica Perrone, Samanta Cupini

Clin Colorectal Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psoriasis caused by pembrolizumab treatment in advanced melanoma: A positive prognostic side effect?
Angelo Massimiliano D'Erme, Cristian Fidanzi, Agata Janowska, Giacomo Allegrini, Cecilia Barbara, Samanta Cupini

Dermatol Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Roberto Moretto, Daniele Rossini, Veronica Conca, Sara Lonardi, Cosimo Rasola, Samanta Cupini

Br J Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Roberto Moretto, Daniele Rossini, Gemma Zucchelli, Sara Lonardi, Francesca Bergamo, Samanta Cupini

Eur J Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, Sara Lonardi, Fotios Loupakis, Samanta Cupini

Lancet Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
Federico Cappuzzo, Andrea Sacconi, Lorenza Landi, Vienna Ludovini, Francesca Biagioni, Samanta Cupini

Clin Colorectal Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Lorenzo Fornaro, Enrico Vasile, Gianluca Masi, Fotios Loupakis, Giacomo Giulio Baldi, Samanta Cupini

Clin Colorectal Cancer· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Lorenzo Fornaro, Giacomo Giulio Baldi, Gianluca Masi, Giacomo Allegrini, Fotios Loupakis, Samanta Cupini

Crit Rev Oncol Hematol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Gianluca Masi, Enrico Vasile, Fotios Loupakis, Samanta Cupini, Lorenzo Fornaro

J Natl Cancer Inst· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Gianluca Masi, Fotios Loupakis, Lisa Salvatore, Lorenzo Fornaro, Chiara Cremolini, Samanta Cupini

Lancet Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.
Gianluca Masi, Lorenzo Fornaro, Samanta Cupini, Fotios Loupakis, Enrico Vasile

Nat Rev Clin Oncol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Gianluca Masi, Fotios Loupakis, Luca Pollina, Enrico Vasile, Samanta Cupini

Ann Surg· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Giacomo Allegrini, Antonello Di Paolo, Elisa Cerri, Samanta Cupini, Federica Amatori

Cancer Chemother Pharmacol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Gianluca Masi, Samanta Cupini, Lorenzo Marcucci, Elisa Cerri, Fotios Loupakis

Ann Surg Oncol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis